Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.
Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback